@article{7d308473a8524e5c922cbe29db53af4c,
title = "Heterogeneity, urgency, generalizability, and enrollment: The HUGE balance in ALS trials",
author = "Chafic Karam and Berry, {James D.}",
note = "Funding Information: C. Karam serves on a Data Safety Monitoring Board for a Phase 2/3 Trial of Arimoclomol in Inclusion Body Myositis (IBM); has received speaker honoraria from Akcea, Alnylam, Alexion, and CSL Behring; served on the editorial boards of the Neurology Resident and Fellow section and Disputes & Debates (letters to the editor) section; and has received consulting honoraria from Akcea, Alnylam, Alexion, Biogen, Cytokinetics, Genzyme, and CSL Behring. J. Berry has served on scientific advisory boards for MT Pharma, Denali Therapeutics, Orion Corporation, Anelixis Therapeutics, and Mayo Clinic; has received travel funding from the ALS Association, Muscular Dystrophy Association, ALS One, and ALS Finding a Cure; holds a patent for MicroRNAs in neurodegenerative disorders (WO2013055865); has received research support from Voyager Therapeutics, Neuraltus Pharmaceuticals, Cytokinetics, Brainstorm Cell Therapeutics, Amylyx Pharmaceuticals, NIH, Muscular Dystrophy Association, ALS Finding a Cure, ALS Association, and ALS One; and receives licensing royalty payments for the aforementioned patent. In addition, his wife is an editorial board member of Neuro-psychopharmacology. Go to Neurology.org/N for full disclosures.",
year = "2019",
month = jan,
day = "29",
doi = "10.1212/WNL.0000000000006837",
language = "English (US)",
volume = "92",
pages = "215--216",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",
}